{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:50:39Z","timestamp":1774950639535,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jpba.2016.06.011","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T12:01:31Z","timestamp":1465646491000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques"],"prefix":"10.1016","volume":"128","author":[{"given":"Marie","family":"Mardal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"Miserez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus R.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.06.011_bib0005","series-title":"New Psychoactive Substances in Europe","author":"EMCDDA","year":"2015"},{"key":"10.1016\/j.jpba.2016.06.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/dta.1800","article-title":"Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers","author":"McLaughlin","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2016.06.011_bib0015","first-page":"777","article-title":"Reinforcing and subjective effects of several anorectics in normal human volunteers","volume":"242","author":"Chait","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2016.06.011_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(02)01830-7","article-title":"Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain","volume":"447","author":"Rothman","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpba.2016.06.011_bib0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1289\/ehp.11022","article-title":"Estimating community drug abuse by wastewater analysis","volume":"116","author":"Zuccato","year":"2008","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jpba.2016.06.011_bib0030","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1016\/j.scitotenv.2010.05.030","article-title":"Illicit drug consumption estimations derived from wastewater analysis: a critical review","volume":"409","author":"van Nuijs","year":"2011","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.jpba.2016.06.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/dta.1938","article-title":"Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS\/MS","author":"Mardal","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2016.06.011_bib0040","article-title":"Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques","author":"Mardal","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2016.06.011_bib0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.scitotenv.2014.06.016","article-title":"Studies on the microbial biotransformation of the novel psychoactive substance methylenedioxypyrovalerone (MDPV) in wastewater by means of liquid chromatography-high resolution mass spectrometry\/mass spectrometry","volume":"493","author":"Mardal","year":"2014","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.jpba.2016.06.011_bib0050","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1021\/es801952h","article-title":"Fate of conjugated natural and synthetic steroid estrogens in crude sewage and activated sludge batch studies","volume":"43","author":"Gomes","year":"2009","journal-title":"Environ. Scie. Technol."},{"key":"10.1016\/j.jpba.2016.06.011_bib0055","article-title":"Microbial biotransformation of five pyrrolidinophenone-type new psychoactive substances in wastewater and a wastewater isolated Pseudomonas Putida strain","author":"Mardal","year":"2016","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.jpba.2016.06.011_bib0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00216-014-8360-0","article-title":"Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC\u2013MS and LC-(HR)-MS(n) techniques","volume":"407","author":"Welter","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2016.06.011_bib0065","series-title":"Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites","author":"Maurer","year":"2007"},{"key":"10.1016\/j.jpba.2016.06.011_bib0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.aca.2015.08.018","article-title":"Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening\u2014exemplified for cardiovascular drugs","volume":"891","author":"Helfer","year":"2015","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2016.06.011_bib0075","first-page":"223","article-title":"The metabolism of phenmetrazine in man and laboratory animals","volume":"5","author":"Franklin","year":"1977","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2016.06.011_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00007691-200404000-00007","article-title":"Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy) piperazine, and pyrrolidinophenone types: a synopsis","volume":"26","author":"Maurer","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2016.06.011_bib0085","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/jms.1859","article-title":"Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC\u2013MS and LC-high-resolution MS and its detectability in urine by GC\u2013MS","volume":"45","author":"Meyer","year":"2010","journal-title":"J. Mass Spectrom. JMS"},{"key":"10.1016\/j.jpba.2016.06.011_bib0090","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1373\/clinchem.2011.172254","article-title":"Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration","volume":"57","author":"Schwaninger","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2016.06.011_bib0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0000000000000240","article-title":"New psychoactive substances: chemistry, pharmacology, metabolism, and detectability of amphetamine derivatives with modified ring systems","volume":"38","author":"Welter-Luedeke","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2016.06.011_bib0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jat\/19.7.563","article-title":"Metabolism of 4-methylaminorex (EU4EA) in the rat","volume":"19","author":"Henderson","year":"1995","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2016.06.011_bib0105","first-page":"388","article-title":"Gas chromatography coupled to high-resolution time-of-flight mass spectrometry to analyze trace-level organic compounds in the environment, food safety and toxicology","volume":"30","author":"Hernandez","year":"2011","journal-title":"TrAC: Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2016.06.011_bib0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.toxlet.2015.11.013","article-title":"Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class","volume":"241","author":"Dinger","year":"2016","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jpba.2016.06.011_bib0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00204-014-1412-6","article-title":"In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach","volume":"90","author":"Dinger","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jpba.2016.06.011_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxlet.2016.06.013","article-title":"What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?","author":"Wagmann","year":"2016","journal-title":"Toxicol. Lett."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516303284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516303284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T08:23:53Z","timestamp":1536654233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516303284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":24,"alternative-id":["S0731708516303284"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.06.011","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}